{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:25:43Z","timestamp":1790717143240,"version":"4.1.0"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.lungcan.2017.04.020","type":"journal-article","created":{"date-parts":[[2017,4,27]],"date-time":"2017-04-27T05:46:12Z","timestamp":1493271972000},"page":"58-61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"special_numbering":"C","title":["Aprepitant for refractory nivolumab-induced pruritus"],"prefix":"10.1016","volume":"109","author":[{"given":"Jiro","family":"Ito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daichi","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaka","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Nagano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Uehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Tomii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2017.04.020_bib0005","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2017.04.020_bib0010","doi-asserted-by":"crossref","first-page":"e10968","DOI":"10.1371\/journal.pone.0010968","article-title":"Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy","volume":"5","author":"Stander","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.lungcan.2017.04.020_bib0015","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2133.1996.tb03598.x","article-title":"Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"135","author":"Rzany","year":"1996","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.lungcan.2017.04.020_bib0020","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1111\/j.1468-3083.2007.02234.x","article-title":"Itch in the community: associations with psychosocial factors among adults","volume":"21","author":"Dalgard","year":"2007","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.lungcan.2017.04.020_bib0025","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S1470-2045(12)70373-X","article-title":"Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study","volume":"13","author":"Santini","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2017.04.020_bib0030","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s00520-010-0895-9","article-title":"Aprepitant against pruritus in patients with solid tumours","volume":"18","author":"Vincenzi","year":"2010","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.lungcan.2017.04.020_bib0035","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1056\/NEJMc1003937","article-title":"Aprepitant for erlotinib-induced pruritus","volume":"363","author":"Vincenzi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2017.04.020_bib0040","first-page":"487","article-title":"More on aprepitant for erlotinib-induced pruritus [Letter]","volume":"364","author":"Mir","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2017.04.020_bib0045","first-page":"665","article-title":"Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma","volume":"164","author":"Booken","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.lungcan.2017.04.020_bib0050","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJMc0906670","article-title":"Aprepitant as an antipruritic agent?","volume":"361","author":"Duval","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2017.04.020_bib0055","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/j.jaad.2011.01.016","article-title":"Aprepitant: evidence of its effectiveness in patients with refractory pruritus continues","volume":"66","author":"Torres","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.lungcan.2017.04.020_bib0060","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1016\/j.jaad.2012.02.008","article-title":"Aprepitant: a novel neurokinin-1 receptor\/substance P antagonist as antipruritic therapy in cutaneous T-cell lymphoma","volume":"67","author":"Ladizinski","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.lungcan.2017.04.020_bib0065","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/dth.12113","article-title":"Treatment of pruritus in early-stage hypopigmented mycosis fungoides with aprepitant","volume":"27","author":"Jimenez-Gallo","year":"2014","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.lungcan.2017.04.020_bib0070","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.ad.2013.07.007","article-title":"Aprepitant in the treatment of refractory pruritus secondary to cutaneous T-cell lymphoma","volume":"105","author":"Borja-Consigliere","year":"2014","journal-title":"Actas Dermosifiliogr."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500217303070?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500217303070?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T20:18:12Z","timestamp":1719173892000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500217303070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":14,"alternative-id":["S0169500217303070"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2017.04.020","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aprepitant for refractory nivolumab-induced pruritus","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2017.04.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}